Cardiovascular Disease (CVD) Phenotyping Core

心血管疾病 (CVD) 表型核心

• 批准号: 10333815
• 负责人: ARSHED A QUYYUMI
• 金额: $ 41.13万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-05-15 至 2027-02-28
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10333815
• 关键词: Autopsy; Biochemical; Biological Markers; Blood; Blood Vessels; Cardiac; Cardiovascular Diseases; Cardiovascular system; Cessation of life; Clinical; Clinics and Hospitals; Collection; Consent; Coronary; Coronary Arteriosclerosis; Data; Data Analyses; Data Collection; Databases; Death Certificates; Diagnosis; Disease Outcome; Documentation; Elements; Enrollment; Equipment; Event; Fatty Liver; Fatty acid glycerol esters; Foundations; Functional disorder; Goals; Health; Health Care Visit; Heart failure; Hepatic; Household; India; Inflammation; Infrastructure; Institution; International; Interviewer; Laboratories; Lead; Left; Link; Lipids; Logistics; Measurement; Measures; Metabolic; Monitor; Myocardial; Myocardial Infarction; Myocardial dysfunction; Participant; Pathway interactions; Peripheral arterial disease; Persons; Phenotype; Physiologic pulse; Play; Process; Program Research Project Grants; Proteins; Protocols documentation; Quality Control; Questionnaires; Reading; Reproducibility; Research; Risk Factors; Role; Sampling; Services; Specimen; Standardization; Stress; Stroke; Structure; Symptoms; Techniques; Testing; Time; Training; Transient Ischemic Attack; Transportation; Urine; Vascular Diseases; Ventricular; Visit; Work; adipokines; adjudication; arterial stiffness; base; cardiovascular imaging; carotid intima-media thickness; clinical phenotype; cohort; coronary artery calcium; coronary calcium scoring; data acquisition; data management; disease phenotype; experience; immune activation; indexing; mortality; novel; phenotypic data; quality assurance; sample collection; secondary outcome; success; synergism; thrombogenesis

PROJECT SUMMARY / ABSTRACT: Cardiovascular Disease (CVD) Phenotyping Core The Cardiovascular Disease (CVD) Phenotyping Core will be responsible for advanced subclinical and clinical CVD phenotyping of all participants enrolled in the Precision Cardiovascular Phenotyping and Pathophysiological Pathways in the CARRS cohort (Precision-CARRS) program project grant (PPG). Responsibilities include providing coordination, expertise, and standardization of all elements related to the proposed phenotyping. The overarching goal of the Core is to obtain the highest quality of CVD subclinical and clinical phenotyping in this cohort and further train existing teams and standardize protocols for (a) novel advanced CVD phenotyping in the field, (b) cardiovascular imaging in central facilities, (c) centralized interpretation of all tests, (d) adjudication of subclinical and clinical CVD events and mortality, (e) blood and urine testing and laboratory services, together with quality assurance and quality control. The CVD Phenotyping Core will be based in Delhi, India and will consolidate and augment existing infrastructure and expertise and leverage a decade of collaborative experience between Emory and India’s leading health research institutions. Specific Aim 1 is to formulate and implement plans for accurate and reproducible phenotyping of sub-clinical CVD that includes measures of (i) functional vascular disease assessed as pulse wave velocity and augmentation index that reflect arterial stiffness; (ii) coronary artery calcium, a reflection of subclinical coronary atherosclerosis; (iii) carotid intima-media thickness and plaque; (iv) hepatic steatosis; and (v) sub-clinical myocardial dysfunction measured as left ventricular systolic or diastolic dysfunction using cardiac echo. Aim 2 will implement plans to standardize adjudication of prevalent and incident clinical CVD events to include atherosclerotic events and occurrence of heart failure. Atherosclerotic events will include incident cardiovascular death, myocardial infarction, and stroke or transient ischemic attacks. Secondary outcomes include diagnosis of angina or coronary or peripheral arterial disease, and revascularization. Heart failure occurrences will include diagnosis of symptomatic Stage C or D heart failure. In Aim 3, we will formulate and implement laboratory sample collection and analysis for all biomarkers analyses, to include traditional risk factors, advanced lipid and metabolic measures, and circulating proteins that reflect activation of pathophysiologic processes associated with CVD. The Core will work in close coordination with the Administrative and Field Coordination Core which will administer the field logistics. Acquired data will be transferred to the Data Management and Analysis Core, and provide curated CVD phenotyping data to all 4 PPG projects.

项目摘要/摘要：心血管疾病 (CVD) 表型核心 心血管疾病（CVD）表型核心将负责先进的亚临床和 对参加精密心血管表型分析的所有参与者进行临床 CVD 表型分析 CARRS 队列 (Precision-CARRS) 计划项目拨款 (PPG) 中的病理生理学途径。 职责包括提供与项目相关的所有要素的协调、专业知识和标准化。 提议的表型分析。核心的总体目标是获得最高质量的 CVD 亚临床和 对该队列进行临床表型分析，并进一步培训现有团队并标准化方案（a）新的 现场先进的 CVD 表型分析，(b) 中央设施的心血管成像，(c) 集中化 所有测试的解释，(d) 亚临床和临床 CVD 事件和死亡率的判定，(e) 血液和 尿液检测和实验室服务，以及质量保证和质量控制。 CVD 表型核心将设在印度德里，并将巩固和增强现有基础设施和 专业知识并利用埃默里大学和印度领先的医疗机构之间十年的合作经验 研究机构。具体目标 1 是制定并实施准确且可重复的计划 亚临床 CVD 的表型分析，包括 (i) 以脉搏评估的功能性血管疾病的测量 反映动脉僵硬度的波速和增强指数； (ii) 冠状动脉钙，反映 亚临床冠状动脉粥样硬化; (iii) 颈动脉内膜中层厚度和斑块； (iv) 肝脂肪变性；和 (v) 亚临床心肌功能障碍，通过左心室收缩或舒张功能障碍测量 心脏回声。目标 2 将实施计划以标准化流行和突发临床 CVD 的裁决 事件包括动脉粥样硬化事件和心力衰竭的发生。动脉粥样硬化事件包括 心血管死亡、心肌梗死、中风或短暂性脑缺血发作。中学 结果包括心绞痛或冠状动脉或外周动脉疾病的诊断以及血运重建。心 心力衰竭的发生将包括症状性 C 期或 D 期心力衰竭的诊断。在目标 3 中，我们将制定 并对所有生物标志物分析实施实验室样本收集和分析，以包括传统风险 因素、先进的脂质和代谢指标以及反映激活的循环蛋白 与 CVD 相关的病理生理过程。核心将与 行政和现场协调核心负责管理现场后勤。获取的数据将是 转移到数据管理和分析核心，并向所有 4 个提供精选的 CVD 表型数据 PPG 项目。